FACTORS AFFECTING LEVELS OF HOPEFULNESS IN ADOLESCENTS WITH THALASSEMIA MAJOR
Öz
The aim of this study was to compare the hopefulness levels of adolescents with thalassemia major (TM) and healthy adolescents, and to determine the impact of some sociodemographic and disease-related characteristics of adolescents with TM on their hopefulness. This cross-sectional and correlational study was conducted in 112 adolescents with TM and 121 healthy adolescents, a total of 233 adolescents. The study sample was selected using the convenience sampling method. While the mean Hopefulness Scale for Adolescents (HSA) score of the adolescents with TM was 1769.9±290.5, it was observed that the mean HSA score of the healthy adolescents was 1824.5±267.9, but the difference was not found to be statistically significant (t=1.491, p=0.137). It was found that, after controlling for the other factors, the father’s educational status impacted the hopefulness score of adolescents with TM and the educational status of a father with an elementary/middle school education had an adverse effect on the hopefulness score (t = -2.601, p=0.011). In this study no difference was found between the hopefulness levels of adolescents with TM and those of healthy adolescents. The only sociodemographic factor that had an impact on the hopefulness of the adolescents with TM was their father’s level of education. Nurses can provide professional help and support to the thalassemic patients who experience hopelessness, and can activate social support systems to help patients cope with such feelings.
Anahtar Kelimeler
Proje Numarası
Kaynakça
- 1. Sayani FA, Kwiatkowski JL. Increasing prevalence of thalassemia in America: Implications for primary care. Annals of Medicine 2015; 47(7), 592-604.
- 2. Vosper J, Evangeli M, Porter JB, Shah F. Psychological factors associated with episodic chelation adherence in thalassemia. Hemoglobin 2018, 42(1), 30-36.
- 3. Ağaoğlu, L. Talasemi ile yaşam (Life with Thalassemia). Türkiye Klinikleri Journal Hem Onc-Special Topics 2010; 3(1), 9-13.
- 4. Cao A, Galanello R. Beta-thalassemia. Genetics in Medicine 201; 12(2), 61-76.
- 5. Topal Y, Topal H, Ceyhan MN, Azık MF, & Kocabaş CN. Beta Talasemi̇ ile Mücadelede Muğla Deneyi̇mleri̇ (Struggling with Beta Thalassemia: Cases from Muğla), Turkish Journal of Pediatric Disease 2015; 9 (3), 226-229.
- 6. Aydınok Y. Iron chelation therapy as a modality of management. Hematology/Oncology Clinics of North America. 2018; 32: 261-275.
- 7. Fortin PM, Fisher SA, Madgwick KV, Trivella M, Hopewell S, Doree C, et. al. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. Cochrane Database of Systematic Reviews 2018; Issue 5. Art. No.: CD012349. 8. Aydınok Y. Thalassemia. Hematology 2012; 17(1), 28-31.
- 9. Uz B, Ongun M, Eliaçık E, Işık A, Aksu S, Büyükaşık Y, ve ark. Beta talasemi major hastalarında yaşam kalitesinin KF-36 ölçeği ile değerlendirilmesi: Tek merkez çalışması, Measuring quality of life with the KF-36 scale in patients with beta thalassemia: a single-site study. Yeni Tıp Dergisi 2013; 30 (2), 70-74.
Ayrıntılar
Birincil Dil
İngilizce
Konular
Sağlık Kurumları Yönetimi
Bölüm
Araştırma Makalesi
Yazarlar
Hüsniye Çalışır
Bu kişi benim
0000-0001-5440-5431
Türkiye
Yayımlanma Tarihi
30 Ocak 2020
Gönderilme Tarihi
19 Kasım 2019
Kabul Tarihi
23 Aralık 2019
Yayımlandığı Sayı
Yıl 2020 Cilt: 6 Sayı: 1






